Drug Trial Radar · NCT07838987
A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014)
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
196
Actual
Start
Dec 21, 2023
Primary completion
Jun 30, 2026
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
- Sponsor type
- Industry
- First posted
- Sep 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of the study is to learn what happens to different doses and forms of Embibatinib in a healthy person's body over time. Researchers will compare what happens to different doses and forms of Embibatinib in a person's body over time when given with or without food, or with or without other medications. The goal of the study is to learn: * What happens to different doses of Embibatinib in a person's body over time when it is given with or without food, or with or without other medications. * About the safety of Embibatinib and if people tolerate it
Conditions
- Healthy
Interventions
EmbibatinibDrug
Oral Tablet
RabeprazoleDrug
The United States commercially marketed 20 mg oral tablet formulation is being used in this trial.
MidazolamDrug
2 mg oral syrup formulation administered as part of the probe substrate cocktail-1 and probe substrate cocktail-2. The United States commercially marketed formulation is being used in this trial.
DigoxinDrug
0.25 mg oral tablet formulation administered as part of the probe substrate cocktail-1. The United States commercially marketed formulation is being used in this trial.
PravastatinDrug
40 mg oral tablet formulation administered as part of the probe substrate cocktail-1. The United States commercially marketed formulation is being used in this trial.
MontelukastDrug
10 mg oral tablet formulation administered as part of the probe substrate cocktail-1. The United States commercially marketed formulation is being used in this trial.
OmeprazoleDrug
40 mg oral tablet formulation administered as part of the probe substrate cocktail-1. The United States commercially marketed formulation is being used in this trial.
ItraconazoleDrug
The United States commercially marketed 200 mg oral capsule formulation is being used in this trial.
WarfarinDrug
5 mg oral tablet formulation administered as part of the probe substrate cocktail-2. The United States commercially marketed formulation is being used in this trial.
RosuvastatinDrug
10 mg oral tablet formulation administered as part of the probe substrate cocktail-2. The United States commercially marketed formulation is being used in this trial.
BosentanDrug
The Europe commercially marketed 125 mg oral tablet formulation is being used in this trial.
QuinidineDrug
The United States commercially marketed 300 mg oral tablet formulation is being used in this trial.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experience a Treatment Emergent Adverse Event (AE)Time frame: Up to approximately 102 days
- Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 102 days
- Number of Participants with Clinically Significant Abnormalities in Systolic Blood PressureTime frame: up to approximately 102 days
- Number of Participants with Clinically Significant Abnormalities in Diastolic Blood PressureTime frame: up to approximately 102 days
- Number of Participants with Abnormal Clinical Hematology Test Results Reported as Adverse EventsTime frame: up to approximately 102 days
- Number of Participants with Abnormal Clinical Chemistry Test Results Reported as Adverse EventsTime frame: up to approximately 102 days
- Number of Participants with Abnormal Urinalysis Results Reported as Adverse EventsTime frame: up to approximately 102 days
- Number of Participants with Clinically Significant Abnormalities in 12-Lead (ECG) FindingsTime frame: up to approximately 102 days
- Area Under the Concentration versus Time Curve from Time 0 to the Last Quantifiable Concentration (AUC0-last) of Embibatinib in PlasmaTime frame: Pre-dose and at designated time points up to 96 hours post dose
- Area Under the Concentration versus Time Curve Extrapolated to Infinite Time (AUC0-Inf) of Embibatinib in PlasmaTime frame: Pre-dose and at designated time points up to 96 hours post dose
- Area Under the Concentration versus Time Curve Over the Dosing Interval (AUCtau) of Embibatinib in PlasmaTime frame: Pre-dose and at designated time points up to 24 hours post dose
- Maximum Observed Concentration of Drug (Cmax) of Embibatinib in PlasmaTime frame: Pre-dose and at designated time points up to 96 hours post dose
- Apparent Terminal Elimination Half-Life (t1/2) of Embibatinib in PlasmaTime frame: Pre-dose and at designated time points up to 96 hours post dose
- Time of Maximum Observed Concentration of Drug (Tmax) of Embibatinib in PlasmaTime frame: Pre-dose and at designated time points up to 96 hours post dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ICON
Millcreek, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.